徳島大学 教育・研究者情報データベース(EDB)

Education and Research Database (EDB), Tokushima University

徳島大学ウェブサイトへのリンク

著作: [炬口 恵理]/[西村 正人]/[峯田 あゆか]/[河北 貴子]/[阿部 彰子]/[苛原 稔]/Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells./[Experimental and Therapeutic Medicine]

ヘルプを読む

「著作」(著作(著書,論文,レター,国際会議など))は,研究業績にかかる著作(著書,論文,レター,国際会議など)を登録するテーブルです. (この情報が属するテーブルの詳細な定義を見る)

  • 項目名の部分にマウスカーソルを置いて少し待つと,項目の簡単な説明がツールチップ表示されます.

この情報をEDB閲覧画面で開く

EID
339196
EOID
939668
Map
0
LastModified
2019年3月2日(土) 20:41:15
Operator
[ADMIN]
Avail
TRUE
Censor
0
Owner
苛原 稔
Read
継承
Write
継承
Delete
継承
種別 必須 学術論文(審査論文)
言語 必須 英語
招待 推奨
審査 推奨
カテゴリ 推奨
共著種別 推奨
学究種別 推奨
組織 推奨
著者 必須
  1. 炬口 恵理
    役割 任意
    貢献度 任意
    学籍番号 推奨 ****
  2. 西村 正人([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.外科系.産科婦人科学])
    役割 任意
    貢献度 任意
    学籍番号 推奨
  3. 峯田 あゆか
    役割 任意
    貢献度 任意
    学籍番号 推奨 ****
  4. 河北 貴子([徳島大学.病院.診療科.小児·周産·女性科.産科婦人科])
    役割 任意
    貢献度 任意
    学籍番号 推奨
  5. 阿部 彰子([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.外科系.産科婦人科学])
    役割 任意
    貢献度 任意
    学籍番号 推奨
  6. 苛原 稔([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.外科系.産科婦人科学])
    役割 任意
    貢献度 任意
    学籍番号 推奨
題名 必須

(英) Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells.

副題 任意
要約 任意

(英) Uterine cervical adenocarcinoma has a poor clinical prognosis when compared with squamous cell carcinoma. Therefore, the development of new treatment strategies for uterine cervical adenocarcinoma is necessary. Src is a proto-oncogene that is important in cancer progression. Dasatinib is a Src inhibitor that has been reported to be effective when used in combination with anticancer drugs. The present study aimed to confirm Src expression in human cervical adenocarcinoma cell lines and to determine the mechanism underlying the inhibitory effect of dasatinib on Src signaling . Western blot analysis was performed to investigate Src expression in cervical adenocarcinoma cell lines (HeLa and TCO-2 cells). The cells were cultured for 48 h with the addition of different concentrations of anticancer drugs (paclitaxel or oxaliplatin). Viable cell count was measured using a colorimetric (WST-1) assay. The concentrations of anticancer agents were fixed according to the results obtained, and the same experiments were performed using the drugs in combination with dasatinib at various concentrations to determine the concentrations that significantly affected the number of viable cells. The presence or absence of apoptosis was investigated using a caspase-3/7 assay. Signal transduction in each cell line was examined using western blotting. Src was activated in the two cell lines, and cell proliferation was significantly suppressed by each anticancer drug in combination with 10 µM dasatinib. Caspase-3/7 activity was also increased and Src signaling was suppressed by each anticancer drug in combination with dasatinib. In conclusion, Src is overexpressed in cervical adenocarcinoma cell lines, and dasatinib inhibits intracellular Src signaling and causes apoptosis. The results of the present study suggest that Src may be targeted in novel therapeutic strategies for cervical adenocarcinoma.

キーワード 推奨
発行所 推奨
誌名 必須 Experimental and Therapeutic Medicine(Spandidos Publications)
(pISSN: 1792-0981, eISSN: 1792-1015)
ISSN 任意 1792-0981
ISSN: 1792-0981 (pISSN: 1792-0981, eISSN: 1792-1015)
Title: Experimental and therapeutic medicine
Title(ISO): Exp Ther Med
Publisher: Spandidos Publications
 (NLM Catalog  (Scopus  (CrossRef (Scopus information is found. [need login])
必須 14
必須 5
必須 4293 4299
都市 任意
年月日 必須 2017年 8月 28日
URL 任意
DOI 任意 10.3892/etm.2017.5061    (→Scopusで検索)
PMID 任意 29067110    (→Scopusで検索)
NAID 任意
WOS 任意
Scopus 任意
機関リポジトリ 112973
評価値 任意
被引用数 任意
指導教員 推奨
備考 任意
  1. (英) Article.ELocationID: 10.3892/etm.2017.5061

  2. (英) Article.PublicationTypeList.PublicationType: Journal Article

  3. (英) KeywordList.Keyword: Src

  4. (英) KeywordList.Keyword: cervical adenocarcinoma

  5. (英) KeywordList.Keyword: dasatinib

  6. (英) KeywordList.Keyword: oxaliplatin

  7. (英) KeywordList.Keyword: paclitaxel